Uterine Fibroid Clinical Trial
Official title:
A Novel Insight Into the Role of Fibroblast Activation and Autophagy in Uterine Fibroid
NCT number | NCT03444987 |
Other study ID # | UF |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 1, 2018 |
Est. completion date | March 1, 2020 |
Verified date | February 2021 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Uterine fibroids (UFs), also called uterine leiomyomas or myomas, are steroid hormone-responsive, benign tumors of the smooth muscle compartment (myometrium) of the uterus. They are the most common neoplasm affecting women in their reproductive age. It is estimated that up to 77% of women develop UF in their life. UFs are one of the leading causes of hospitalisations for gynaecological disorders and are the most frequent reason for hysterectomy. According to relevant literature, 40%-60% of all the hysterectomies performed are due to the presence of UFs.
Status | Completed |
Enrollment | 35 |
Est. completion date | March 1, 2020 |
Est. primary completion date | November 1, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | N/A to 50 Years |
Eligibility | Inclusion Criteria: i. Premenopausal women (age ? 50) with uterine fibroids who are diagnosed through clinical gynecological, ultrasound and other auxiliary examinations. ii. Patients who exhibit a normal coagulation function. Exclusion Criteria - i. Patients who have a previous history of myomectomy or with ovarian malignancy and borderline tumors ii. Patients who are subsequently diagnosed with uterine adenomyosis. iii. Pregnant women. iv. Patients who receive hormonal treatment within three months before surgery. v. Patients with history of coronary artery disease, hypertension, liver cirrhosis or hematologic disorders. |
Country | Name | City | State |
---|---|---|---|
Egypt | Assiut university -Faculty of medicine- Departement of Biochemistry | Assiut |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Egypt,
Bainbridge TW, Dunshee DR, Kljavin NM, Skelton NJ, Sonoda J, Ernst JA. Selective Homogeneous Assay for Circulating Endopeptidase Fibroblast Activation Protein (FAP). Sci Rep. 2017 Oct 2;7(1):12524. doi: 10.1038/s41598-017-12900-8. — View Citation
Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014 Jun;8(5-6):454-63. doi: 10.1002/prca.201300095. Epub 2014 Mar 24. Review. — View Citation
Islam MS, Ciavattini A, Petraglia F, Castellucci M, Ciarmela P. Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics. Hum Reprod Update. 2018 Jan 1;24(1):59-85. doi: 10.1093/humupd/dmx032. Review. — View Citation
Luo N, Guan Q, Zheng L, Qu X, Dai H, Cheng Z. Estrogen-mediated activation of fibroblasts and its effects on the fibroid cell proliferation. Transl Res. 2014 Mar;163(3):232-41. doi: 10.1016/j.trsl.2013.11.008. Epub 2013 Nov 20. — View Citation
McWilliams MM, Chennathukuzhi VM. Recent Advances in Uterine Fibroid Etiology. Semin Reprod Med. 2017 Mar;35(2):181-189. doi: 10.1055/s-0037-1599090. Epub 2017 Mar 9. Review. — View Citation
Moore AB, Yu L, Swartz CD, Zheng X, Wang L, Castro L, Kissling GE, Walmer DK, Robboy SJ, Dixon D. Human uterine leiomyoma-derived fibroblasts stimulate uterine leiomyoma cell proliferation and collagen type I production, and activate RTKs and TGF beta receptor signaling in coculture. Cell Commun Signal. 2010 Jun 10;8:10. doi: 10.1186/1478-811X-8-10. — View Citation
Räsänen K, Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell Res. 2010 Oct 15;316(17):2713-22. doi: 10.1016/j.yexcr.2010.04.032. Epub 2010 May 6. Review. — View Citation
Wang H, Wu Q, Liu Z, Luo X, Fan Y, Liu Y, Zhang Y, Hua S, Fu Q, Zhao M, Chen Y, Fang W, Lv X. Downregulation of FAP suppresses cell proliferation and metastasis through PTEN/PI3K/AKT and Ras-ERK signaling in oral squamous cell carcinoma. Cell Death Dis. 2014 Apr 10;5:e1155. doi: 10.1038/cddis.2014.122. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparing FAP and autophagy markers in patient and control groups. | Explore difference in level of fibroblast activation marker (FAP) and autophagy markers (LC3 and P62) in UF tissue samples compared to normal myometrial samples (1 cm from the UF lesion). | 1 year | |
Secondary | Study signaling pathway linking FAP and autophagy which ma considered as a therapeutic target | Investigate the correlation between fibroblast activation and autophagy through PI3/AKT signaling pathway and their role in the pathogenesis of UF through estimation of AKT protein expression in UF tissue samples compared to normal myometrial samples 1 cm from the UF lesion. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04073485 -
Microwave Ablation for Uterine Fibroids
|
N/A | |
Recruiting |
NCT04519593 -
ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma
|
N/A | |
Recruiting |
NCT01239641 -
High Intensity Focused Ultrasound Ablation Virus Myomectomy to Treat Uterine Fibroids
|
Phase 4 | |
Recruiting |
NCT04748978 -
OPPIuM Technique and Myolysis With Diode Laser Dwls
|
N/A | |
Not yet recruiting |
NCT04191603 -
TWO DİFFERENT ELECTROSURGERY DEVICES AS MONOPOLAR HOOC AND PLASMAKINETIC BIPOLAR SPATULA EFFECTIVENESS DURING COLPOTOMY
|
N/A | |
Terminated |
NCT04132349 -
Ulipristal Acetate in Symptomatic Uterine Fibroid
|
Phase 4 | |
Completed |
NCT03412890 -
LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
|
Phase 3 | |
Completed |
NCT03021720 -
Satisfaction of Patients With Trans-Arterial Radial Access: Quality of Life in Uterine Fibroid Embolization Trial
|
N/A | |
Recruiting |
NCT04209036 -
Can 3D Laparoscopy Improve Surgical Performances in Surgeons in Training?
|
||
Completed |
NCT05086770 -
Comparison of Pain After Uterine Artery Embolization Using Gelatin Microsphere or Tris-acryl Gelatin Microsphere
|
N/A | |
Recruiting |
NCT05416424 -
Life Study: Lifestyle Intervention in Fibroid Elimination
|
N/A | |
Not yet recruiting |
NCT05695690 -
Role of US in Uterine Fibroids in Comparison With MRI Using FIGO Classification
|
||
Enrolling by invitation |
NCT06430320 -
Ascertaining Longterm Outcomes of Fibroid Treatments
|
||
Completed |
NCT04832906 -
UA Versus UAE in Treatment of Fibroids
|
Phase 4 | |
Active, not recruiting |
NCT06244251 -
Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids
|
N/A | |
Not yet recruiting |
NCT06153667 -
Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)
|
||
Not yet recruiting |
NCT03450421 -
Safety and Efficacy of Actamax™Adhesion Barrier in Women Undergoing Laparoscopic Abdominopelvic Surgery/Myomectomy
|
N/A | |
Not yet recruiting |
NCT05840042 -
Epidemiology and Risk Factors of Uterine Fibroids in China
|
||
Completed |
NCT04345003 -
MR Elastography Parameters Impact on MR-HIFU Efficacy in Uterine Fibroids
|
N/A | |
Recruiting |
NCT03118037 -
Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry
|